The immunomodulatory activity of thymulin and related analogues in vivo is not well characterized in the CNS. We have previously provided evidence for an anti-inflammatory potential of thymulin in downregulating proinflammatory cytokines in a NF-B-dependent mechanism in vitro. Furthermore, we have shown that intracerebroventricular (ICV) treatment with thymulin in the hippocampus (HC) reduced the nuclear localization and activation of NF-B, an effect mediated by the IB-α/pIB-α pathway in vivo. ICV stereotaxic injection of endotoxin (ET) differentially upregulated the nuclear translocation /expression of NF-B 1 (p50), NF-B 2 (p52), RelA (p65), RelB (p68) and c-Rel (p75) in the HC. Pretreatment with thymulin followed by ET exposure reduced the nuclear translocation of NF-B subunits. The anti-inflammatory effect of thymulin seems to be mediated via the IB- pathway since thymulin downregulated ET-induced phosphorylation of IB-. Stereotaxic pretreatment with synthetic peptide analogue of thymulin (PAT) reduced the nuclear translocation of NF-B subunits, an effect mediated by downregulating the phosphorylation of IB-. EMSA revealed dose-dependent inhibition of NF-B/DNA activation mediated by ICV ET. These results indicate that the anti-inflammatory effect of thymulin/PAT, mediated by IB-, is NF-B-dependent and involves the downregulation of the nuclear translocation of various NF-B subunits and their subcellular activation.